Similarly, a previous network meta-analysis demonstrates that the probability of treatment ranking was higher with PD-1 inhibitor than PD-L1 inhibitor for previously treated NSCLC [27]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.